Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927016 | 0.85 | ALDH1A1 (0.69) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL3698220 | 0.82 | NPC1 (0.49) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL5452605 | 0.81 | NPC1 (1.00) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL27522330 | 0.80 | ALDH1A1 (0.62) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL1385749 | 0.80 | ALDH1A1 (0.62) | NPC1ALDH1A1HTTRAB9APAX8 | |
| Carbamic Acid SCHEMBL6468271 | 0.80 | NPC1 (0.62) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL5694553 | 0.80 | TSPO (0.72) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL10921379 | 0.80 | ALDH1A1 (0.62) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL1385745 | 0.80 | NPC1 (0.62) | NPC1ALDH1A1HTTRAB9APAX8 | |
| SCHEMBL9679324 | 0.79 | ALDH1A1 (0.52) | NPC1ALDH1A1HTTRAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965098-B2 | Pressing mold friendly binder for lignocellulosic composites | HUNTSMAN INTERNATIONAL LLC | 2024-04-23 | — | — | US | disclosed |
| EP-2734364-B1 | BINDER COMPOSITION FOR USE IN CELLULOSIC COMPOSITES AND METHODS RELATED THERETO | HUNTSMAN INT LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20200277499-A1 | PRESSING MOLD FRIENDLY BINDER FOR LIGNOCELLULOSIC COMPOSITES | HUNTSMAN INTERNATIONAL LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3687677-A1 | PRESSING MOLD FRIENDLY BINDER FOR LIGNOCELLULOSIC COMPOSITES | Huntsman International LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111163860-A | Compression-molding friendly adhesive for lignocellulosic composites | 亨斯迈国际有限责任公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019067201-A1 | PRESSING MOLD FRIENDLY BINDER FOR LIGNOCELLULOSIC COMPOSITES | HUNTSMAN INTERNATIONAL LLC (US) | 2019-04-04 | — | — | WO | disclosed |
| US-9505711-B2 | Method for purifying mixtures comprising 4,4′-methylenediphenyl diisocyanate | BASF SE (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505711-B2 | Method for purifying mixtures comprising 4,4′-methylenediphenyl diisocyanate | BASF SE (DE) | 2016-11-29 | — | — | US | disclosed |
| EP-2640696-B1 | PROCESS FOR PURIFYING MIXTURES COMPRISING 4,4'-METHYLENE DIPHENYL DIISOCYANATE | BASF SE (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2640695-B1 | PROCESS FOR PURIFYING MIXTURES COMPRISING 4,4'-METHYLENE DIPHENYL DIISOCYANATE | BASF SE (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | ALMIRALL, S.A. (ES) | 2004-12-30 | — | — | US | disclosed |
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | LABORATORIOS ALMIRALL S.A. (ES) | 2004-12-02 | — | — | US | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
| EP-1345937-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051841-A1 | QUINUCLIDINE CARBAMATE DERIVATIVES AND THEIR USE AS M3 ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| US-4136180-A | HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS | PFIZER INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4088766-A | PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4062960-A | Hypolipidemic alkenesulfonamides | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4001256-A | PROSTAGLANDIN PRODUCTION IN MAMMALS | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242629-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM2, CHRM1 | NPC1 1428/4885ALDH1A1 1591/4885HTT 4041/4885 |
| US-20040266816-A1 | Quinuclidine carbamate derivatives and their use as M3 antagonists | CHRM3, CHRM1, CHRM2 | NPC1 1564/4885ALDH1A1 1413/4885HTT 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.